SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Oravetz who wrote (202)8/25/2000 12:40:47 PM
From: Jim Oravetz  Read Replies (2) of 370
 
Vion Pharmaceutical Inc. (VION) initiated additional Phase I intravenous human clinical trials on its tumor amplified protein expression therapy, or Tapet, bacterial vector.

Tapet is the designation for Salmonella bacteria that are genetically altered to reduce or prevent the usual consequences of infection.

In a press release Friday, the company said it expects to enroll 20 to 30 patients at the additional clinical trial sites in Beth Israel Deaconess Medical Center of Boston and at Cleveland Clinic Foundation.

The studies are designed to determine Tapet's safety and tolerability in a broad group of patients with advanced cancer, and to provide information regarding Tapet's ability to penetrate and preferentially replicate and accumulate within tumors of selected patients.

Vion said information from the study may also provide a scientific and clinical foundation for future human clinical trials using armed or unarmed Tapet vectors, as well as unarmed vectors in combination with standard anticancer agents.

On March 28, Vion received approval to begin Phase I Tapet trials at the National Cancer Institute, Bethesda, Md.

On July 24, Vion began a Phase I clinical trial on Tapet in Royal Marsden Hospital, Sutton, U.K. The company expected to enroll 48 patients in the study.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News